The Tool Desk
Outbyte PC Repair FREERepair Windows errors before they cause bigger problemsFix Now →Outbyte Driver Updater FREEScan for outdated or missing drivers - takes under a minuteDriver Scan →DT-109 is the experimental drug behind the headline. In studies of mice and nonhuman primates, the glycine-based tripeptide improved severe metabolic dysfunction-associated steatohepatitis (MASH) by reducing ammonia-producing gut bacteria, repairing the intestinal barrier and dampening liver inflammation. It has not been tested in human clinical trials, approved for patients or shown to reverse human liver fibrosis.
What the new fatty liver drug actually is
Researchers at Michigan Medicine developed DT-109 as an investigational compound aimed at the gut-liver axis rather than the liver alone. The study, led by Pengxiang Qu and colleagues, is titled “Metabolic dysfunction–associated steatohepatitis exacerbated by Clostridium perfringens-derived ammonia is attenuated by tripeptide DT-109” and was published in the Journal of Clinical Investigation in 2026 (DOI 10.1172/JCI200522).
As an Amazon Associate I earn from qualifying purchases.
MASH is the progressive form of metabolic fatty liver disease in which fat accumulation is accompanied by liver-cell injury and inflammation. Persistent inflammation can produce fibrosis and, in some people, cirrhosis or liver cancer. Michigan Medicine’s 2026 institutional summary estimates that about 7% of people worldwide have MASH; that is a prevalence estimate, not a DT-109 treatment result.
What’s actually slowing this PC down?
Pick the symptom - the matching free tool is one click away.
How DT-109 is supposed to repair the gut
Ammonia from an overgrown bacterium
The investigators linked severe MASH in their models to an overgrowth of Clostridium perfringens, a bacterium that produces ammonia in the intestine. Their proposed sequence is that excess ammonia injures the intestinal lining. A damaged lining becomes more permeable, allowing ammonia and other microbial products to cross into the bloodstream.
#1 Best Overall
The gut-liver inflammatory pathway
Once those products reach the liver, they can activate inflammatory immune responses, including CD8+ T cells. That creates a feedback loop in which gut damage contributes to liver inflammation and worsening MASH. DT-109 reduced the abundance of the ammonia-producing bacterium and lowered ammonia levels in the gut. It also strengthened the intestinal epithelial barrier, limiting the systemic movement of inflammatory microbial products.
Y. Eugene Chen, M.D., Ph.D., the study’s senior author and Frederick G. L. Huetwell Professor of Cardiovascular Medicine, said: “We see clear evidence that DT-109 protects the gut epithelial barrier, reducing the systemic influx of harmful microbial products that are thought to contribute to MASH development and progression.”
Jifeng Zhang, Ph.D., a co-author and research professor, described the same mechanism as a connection between microbiota modulation and liver protection: “DT-109 connects microbiota modulation with liver protection by restoring gut barrier integrity and limiting the systemic translocation of ammonia and other pro-inflammatory microbial products within the gut-liver axis.”
What the study tested—and what it did not
Evidence from animal models
The report describes experiments in mice and nonhuman primates. In those models, DT-109 was associated with less Clostridium perfringens, lower intestinal ammonia, a stronger gut barrier and reduced liver inflammation. Those findings support a biological mechanism, but they do not establish that the compound reverses MASH or fibrosis in people.
Human results are not available
The cited report says further testing is needed before human clinical trials. It provides no human response rate, dose, adverse-event rate, long-term safety result or price. There is therefore no evidence yet that DT-109 is safe, effective or tolerable for patients, and no established treatment schedule for doctors to prescribe.
Is DT-109 available yet?
No. DT-109 remains an experimental, preclinical compound. It is not an approved prescription drug and is not available through pharmacies or a legitimate consumer supplement. A report-associated licensee, Diapin Therapeutics, may provide a route for future development, but the program’s clinical-trial timing, enrollment and access have not been established in the cited material.
Patients should not attempt to recreate the approach with probiotics, fermented products or “gut” supplements. The study tested a specific tripeptide and a defined disease mechanism; it did not show that over-the-counter products lower ammonia, repair the intestinal barrier or treat MASH.
How DT-109 differs from the approved option Rezdiffra
DT-109 and Rezdiffra address different stages of evidence and different biological targets. Rezdiffra (resmetirom) is an approved prescription option for eligible adults with noncirrhotic MASH/NASH and moderate or advanced fibrosis. The U.S. Food and Drug Administration’s 2024 efficacy decision relied on Trial 1, which enrolled 888 adults with biopsy-confirmed disease.
Best Value
| Characteristic | DT-109 | Rezdiffra (resmetirom) |
|---|---|---|
| Regulatory stage | Investigational; preclinical | FDA-approved in 2024 for an eligible noncirrhotic MASH/NASH population |
| Evidence described here | Mice and nonhuman primates | Trial 1 involving 888 adults with biopsy-confirmed NASH/MASH and moderate or advanced fibrosis without cirrhosis |
| Primary target | Gut barrier, microbiota and ammonia in the gut-liver axis | Thyroid-hormone receptor-beta pathway and liver metabolism |
| Human efficacy data | None reported | FDA-reviewed clinical-trial evidence supports its approved use |
| Human dose and adverse-event rate | Not established | Specific figures are not stated in the cited DT-109 report |
| Availability | Not available for patient use | Available by prescription to patients who meet the approved indication |
Because their mechanisms and evidence stages differ, DT-109 should not be presented as an alternative equivalent to an approved therapy. A hepatologist can determine whether an approved treatment, clinical-trial participation or management of metabolic risk factors is appropriate for an individual patient.
Independent reader supportYour contribution helps us test, update, and keep practical guides available for everyone.Can DT-109 reverse MASH or liver fibrosis?
The animal findings suggest that repairing the gut barrier may reduce one driver of liver inflammation, and that could eventually help prevent or reverse disease. They do not prove reversal of established human MASH, removal of human fibrosis or prevention of cirrhosis. Those questions require carefully controlled human trials with validated liver and safety outcomes.
Elliot Tapper, M.D., Academic Director of Hepatology at Michigan Medicine, said: “What patients with MASH need is a safe and effective therapy capable of improving their liver and heart health — of course we are excited about these developments.” That statement reflects the potential significance of the mechanism, not evidence that DT-109 is ready for clinical care.
Free tools Windows power users keep installed
One-click scans. No signup required.
Quick Recap
What patients should do now
- Do not stop, start or substitute prescription treatment based on the DT-109 animal study.
- Ask a liver specialist which approved options and monitoring plans fit your fibrosis stage and whether a registered clinical trial is appropriate.
- Be skeptical of products claiming to contain DT-109 or to reproduce its gut-barrier effect; the compound is not an approved consumer medicine.
- Look for future human-trial results before judging DT-109’s dose, safety, effectiveness or ability to change fibrosis.
Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.
